AUG 25 2026
Xspray Pharma AB — Dasynoc (dasatinib)
for chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL)
Accepted FEB 26 2026.
About
Chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) are blood cancers where abnormal white blood cells multiply uncontrollably. Dasynoc (dasatinib) blocks signals that drive cancer cell growth by targeting specific proteins involved in cell division. This approach may help slow disease progression by interfering with the mechanisms that allow leukemia cells to thrive.
Pivotal trial
This is a prospective, multicenter study conducted within the Chinese Children's Cancer Group (CCCG). The study aims to evaluate whether the addition of three novel agents, dasatinib, venetoclax and homoharringtonine, can improve the minimal residual disease (MRD)-negative remission rate, enhance event-free survival (EFS), and reduce the cumulative incidence of relapse (CIR) in pediatric patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Dasynoc
- Clinical Implications Remain After Dasatinib CRL in CML/ALL - CancerNetwork
- FDA Rejects Dasatinib (Dasynoc) for Leukemia - Oncology News Central
- Xspray's Dasynoc is latest drug shot down by FDA due to manufacturing issues - FirstWord Pharma
- Xspray Pharma's CEO: "XS003 shows that we are building a powerhouse – Dasynoc is just the beginning" - Biostock
- FDA Accepts NDA Resubmission for Dasynoc in CML - OncLive